MASCC/ESMO Antiemetic Guidelines
©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide. 

Organizing and Overall Meeting Chairs 
Matti Aapro, MD, Richard J. Gralla, MD, Jørn Herrstedt, MD, DMSci, Alex Molassiotis, RN, PhD, Fausto Roila, MD for the ESMO/MASCC Guidelines Working Group.

The MASCC/ESMO Antiemetic Guidelines have been updated as of March, 2016. The revised guidelines are based on the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015, and have been endorsed by both MASCC and ESMO. 
MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting: ESMO Clinical Practice Guidelines.
F. Roila, A. Molassiotis, J. Herrstedt, M. Aapro, R. J. Gralla, E. Bruera, et al. On behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. Ann Oncol. 2016; 27(suppl 5):v119-v133, 2016. 

The previous version of the Antiemetic Guidelines was based on the Consensus Guideline Meeting held in Perugia, Italy, June 2009. 
Guideline Update for MASCC and ESMO in the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting: Results of the Perugia Consensus Conference.
F. Roila, J. Herrstedt, M. Aapro, R. J. Gralla, L. H. Einhorn, E. Ballatori, et al. On behalf of the ESMO/MASCC Guidelines Working Group. Ann Oncol. 2010;21(suppl 5):v232-43.

Consensus Recommendation Papers
The full-text versions of the 2016 MASCC/ESMO Consensus Recommendation papers from Supportive Care in Cancer (Vol. 27, Supplement 5, 2016), which reflect the conclusions of the 2015 Consensus Conference, are available to MASCC Members, courtesy of MASCC and Springer. 

The full-text versions of the 2010 MASCC/ESMO Antiemetic Guideline papers from Supportive Care in Cancer (Vol. 19, Supplement 1, March 2011) are also available to MASCC Members, courtesy of MASCC and Springer. These papers represent a detailed summary of the deliberations from the Consensus Guideline Meeting in Perugia, Italy, June 2009. 

Guideline Slide Set
English - Version 1.2 (2016)  Available in PDF   and powerpoint   (pptx)

Guideline Slide Set Translations
Translation Policy - For more translation information please contact MASCC Study Group Coordinator, Leslie Johnson

Translations of the 2016 Guidelines Version 1.2
German ,  - (Version 1.2 ) Oct 2016, Translation by Karin Jordan, Franziska Jahn, Petra Feyer, Petra Ortner, Mascha Poemmerl
Japanese ,  - (Version 1.2 ) May 2016 - Translation by Springer and reviewed by JASCC

Translations of the 2010 Guidelines
Arabic  - June 2010, Translated by Bassam Estfan
Chinese ,   - April 2011, Translation provided by Shiyong Wang
French ,  - April 2012
Greek ,  - Nov 2010, Translated by Ourania Nicolatou-Galitis and Erofili Papadopoulou
Portuguese ,  - March 2011
Russian ,  - August 2011, Translated by Anton Snegovoy
Serbian ,  - April 2013, Translated by Snezana Bosnjak, Jelena Dimitrijevic and Ana Vujovic
Spanish ,  - August 2011, Translated by Alvaro Menendez
Turkish ,  - August 2010, Translated by Ahmet Sezer, Ali Ayberk Besen, Huseyin Abali

MASCC Endorsed Guideline Partnerships

Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting Due to Chemotherapy in Pediatric Cancer Patients
The Pediatric Oncology Group of Ontario (POGO) has published "Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting due to Chemotherapy in Pediatric Cancer Patients” (April 2014). This evidence-based guideline contains recommendations for optimizing control of anticipatory nausea and vomiting  in children from 1 month to 18 years of age who are receiving chemotherapy. Recommendations for both pharmacological and nonpharmacological interventions are included.  >> Read the Guideline  
*Disclaimer* The evidence used in formulating this guideline was rated as "low level" by the authors and much of it was derived from evidence in the adult population, rather than a pediatric population. While the conclusions have face validity, the strength of the recommendations is limited by a dearth of high-quality data. There remains a need for more studies in the pediatric population. 

Acute AINV Guideline for Pediatric Cancer Patients
The Pediatric Oncology Group of Ontario (POGO) has published “Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients” (April 2014). The purpose of this guideline is to provide healthcare providers with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of antineoplastic administration).  >> Quick Review Summary

MASCC Antiemetic Guidelines ©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide.
For Questions or additional information, contact Executive Director, Melissa Chin,  [email protected]